-transparent.png){kind=logo}
Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results. 1999
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
Divisione di Oncologia Medica, Ospedale S. Carlo Borromeo, Milan, Italy.
Clinical data have supported the combination of subcutaneous r-interleukin-2 (rIL-2) and r-interferon-alpha (rIFN-alpha) as a promising combination for advanced renal cell carcinoma (RCC), with a reduced toxicity. We evaluated the activity and safety of this outpatient immunotherapy and report on the clinical results and the long-term survival analysis. Objective responses was observed in 9 of 50 (18%) patients, 6 of whom (12%) achieved a complete response. Overall median survival is 12 months, six patients were surviving at a median follow-up of 24 months, and three (6%) are still progression-free.
Related Publications
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
September 1994,
Der Urologe. Ausg. A,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
January 1993,
Cancer biotherapy,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
April 1999,
American journal of clinical oncology,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
August 1997,
Cancer immunology, immunotherapy : CII,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
June 2006,
Cancer biotherapy & radiopharmaceuticals,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
January 1993,
European journal of cancer (Oxford, England : 1990),
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
March 1997,
International journal of oncology,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
February 1996,
The Journal of urology,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
November 2001,
Cancer,
M C Locatelli, and
G Facendola, and
G Pizzocaro, and
L Piva, and
C Pegoraro, and
E B Pallavicini, and
A Signaroldi, and
M Meregalli, and
F Lombardi, and
G D Beretta, and
F Scanzi, and
R Labianca, and
G Dallavalle, and
G Luporini
April 2006,
American journal of clinical oncology,
